MUC13 and pancreatic ductal adenocarcinoma: Using a novel digital EV screening method technique, Yang et al. evaluated 22 plasma-based markers that were observed to be differentially expressed in pancreatic ductal adenocarcinoma (PDAC), especially mucin-based markers (MUC1, MUC2, MUC4, MUC5AC, MUC6, and MUC13), as well as molecules strictly related to PDAC vesicles (EpCAM, EpHA2, Glypican 1, STMN1, and TSP1) [89,90].